Author: admin

Dr. Katherine Cwiklinski selected for IAOTP’s Empowered Woman Award

Dr. Katherine Cwiklinski selected for IAOTP’s Empowered Woman Award

Dr. Katherine Cwiklinski, Proprietor of Paragon Physical Therapy, was recently selected as Empowered Woman of the Year by the International Association of Top Professionals (IAOTP). Her exemplary role as a female entrepreneur and talented professional displays her influence, capability, and proficiency.

Inclusion with the International Association of Top Professionals (IAOTP) is an honor; only a few women are chosen for this distinction based on their years of experience, professional accomplishments, academic achievements, leadership abilities, and contributions to their communities. These women empower others with innovation and compassion to reach their goals while creating change for future generations. Dr. Katherine Cwiklinski will be honored for this distinction at IAOTP’s Annual Awards Gala.

www.iaotp.com/award-gala 

The President of IAOTP, Stephanie Cirami, stated, “We are honored to have Dr. Katherine Cwiklinski as part of the IAOTP family. She provides visionary leadership as a female entrepreneur, and her extraordinary accomplishments prove she will empower women worldwide. We look forward to celebrating all her merits at the Annual Awards Gala and cannot wait to see more amazing things from this woman.“

With more than two decades of experience in the industry, Dr. Cwiklinski has certainly proven herself as an expert in her field. As a dynamic, results-driven leader, Dr. Katherine is the proprietor of Paragon Physical Therapy, and she is also a Certified Strengthening and Conditioning Specialist via the National Strength and Conditioning Association. 

Dr. Katherine’s areas of expertise include but are not limited to orthopedic and sports physical therapy, joint replacement rehabilitation, acute stroke sufferers, and post-surgical patients. She uses manual approaches to treat the shoulder, hip, knee, ankle, and spine. Dr. Katherine is also a qualified Ergonomic Assessment Expert from the Back School of Atlanta. She conducts ergonomic work site inspections for businesses in order to provide a safe and pleasant work environment. Katherine is also trained in LSVT for the treatment of Parkinson’s disease.

Before embarking on her career path, Dr. Cwiklinski graduated from the University of Medicine and Dentistry with a Doctorate in Physical Therapy (DPT) in 2005 (currently named Rutgers University) 

Throughout her illustrious career, Dr. Cwiklinski has received many awards and accolades and has been recognized worldwide for her accomplishments. Dr. Katherine Cwiklinski was awarded Top Doctor of the Year In Physical Therapy 2023 by the International Association of Top Professionals (IAOTP). She will be considered for a feature article in TIP (Top Industry Professionals) Magazine this year and to be featured on the famous Nasdaq billboard in Times Square NYC. Dr. Katherine Cwiklinski will be honored as Empowered Woman of the Year at IAOTP’s Annual Awards Gala at the magnificent Plaza Hotel this December in NYC.

In addition to her successful career, Dr. Cwiklinski also emphasizes the importance of networking, which is essential for gaining patient referrals. She stays current on PT news by attending conferences and submitting articles to the APTA’s journal. She aspires to expand her practice, create a second location, and serve as a guide to other aspiring professionals as she looks to the future.

Looking back, Dr. Katherine attributes her success to her perseverance, work ethic, and the mentors she has had along the way. When not working, she enjoys traveling and spending time with her family. In the future, she hopes to inspire and influence those getting into the field.

For more information, please visit: www.paragonpt.net

Watch her video:

https://www.youtube.com/watch?v=gW5x4oTruC4&t=1s

About IAOTP

The International Association of Top Professionals (IAOTP) is an international boutique networking organization that handpicks the world’s finest, most prestigious top professionals from different industries. These top professionals are given an opportunity to collaborate, share their ideas, be keynote speakers, and help influence others in their fields. This organization is not a membership that anyone can join. You must be asked by the President or be nominated by a distinguished honorary member after a brief interview. 

IAOTP’s experts have given thousands of top prestigious professionals worldwide the recognition and credibility they deserve and have helped build their branding empires. IAOTP prides itself on being a one-of-a-kind boutique networking organization that handpicks only the best of the best and creates a networking platform that connects and brings these top professionals to one place.

For more information on IAOTP, please visit: www.iaotp.com

Media Contact
Company Name: IAOTP
Contact Person: Media Relations
Email: Send Email
Phone: (212) 634-4427
Country: United States
Website: https://iaotp.com

Dr. Jacqueline Mohair selected as Top Transformational Business and Life Strategist Advocate of the Year by IAOTP

Dr. Jacqueline Mohair selected as Top Transformational Business and Life Strategist Advocate of the Year by IAOTP

Dr. Jacqueline Mohair, Transformational Business and Life Strategist and Life Coach, was recently selected as Top Transformational Business and Life Strategist Advocate for 2024 by the International Association of Top Professionals (IAOTP) for her outstanding leadership, dedication, and commitment to the industry.

Inclusion with the International Association of Top Professionals is an honor in itself; only a few members in each discipline are chosen for this distinction. These special honorees are distinguished based on their professional accomplishments, academic achievements, leadership abilities, longevity in the field, other affiliations, and contributions to their communities. All Honorees are invited to attend the IAOTP annual award gala at the end of this year for a night to honor their achievements.

www.iaotp.com/award-gala

With more than two decades of experience in the industry, Dr. Mohair has certainly proven herself as an expert in her field. As a dynamic, results-driven leader, Ambassador Dr. Jacqueline Mohair is a known Transformational Business and Life Strategist, Advocate, Professor, Life Coach, Minister, Serial Entrepreneur, and Ambassador to the UN. In her business services/sales professions, Dr. Mohair has proven her excellence in driving product development initiatives to successful completion by providing excellent written and oral communication, project management, social media management, facilitation, negotiation, healthcare field, and analysis skills. In addition, she skillfully has developed and implemented integrated media strategies with a focus on the importance of social media to produce relationships and lead generation. With more than 20 years of marketing and sales experience, and 15 years as an entrepreneur, Dr. Mohair has helped hundreds of small business owners, corporate professionals, and non-profits succeed. She has also reached the top position in 3 network marketing companies.

In addition, Ambassador Dr. Mohair is a premiere Life Coach helping women to turn their passion into profits and dreams into reality. An advocate for change, who is passionate about empowering people to succeed in life and business, she teaches mankind how to birth vision and turn their pain into purpose. Her motto is “You were created by a creator who’s given you Power to Create from the Well Within”.

Dr. Jacqueline Mohair was appointed to Word of Life Christian Fellowship/Word of Life Ministries International (WOLMI), Third World Leaders Association Ambassador to the United Nations (UN) Economic and Social Council (UNECOSOC) on January 26, 2015. The appointment of Ambassador was granted by The United Nations Headquarters in Geneva, Switzerland. Word of Life Christian Fellowship/Word of Life Ministries International is a Non-Governmental Organization (NGO) in special consultative status with the Economic and Social Council of the UN and the first Full Gospel Ministry granted consultative status with the UN. Currently, she serves as the Chief NGO Ambassador to the United Nations for Trinity Girls Network Corp. An organization with ECOSOC accreditation with the United Nations.

Dr. Jacqueline’s areas of expertise include but are not limited to social media marketing, personal branding, sales and sales management, product development, marketing strategies, lead generation, new business development, sales operations, fundraising, recruiting, strategic partnerships, public speaking, leadership, coaching, public relations, community engagement, and entrepreneurship.

Before embarking on her career path, Dr. Mohair received her B.A. in Marketing in 1994 from Mississippi State University. Following that, she received her first Master’s degree in Educational Leadership from Argosy University in 2008 and a second Master’s degree in Internet Marketing in 2011 from Full Sail University. In 2014, Jacqueline earned her first Doctorate in Philosophy in Christian Leadership and then again in 2015 received her second Doctorate of Business Administration – Marketing from Argosy University Atlanta.

Throughout her illustrious career, Dr. Mohair has received many awards and accolades and has been recognized worldwide for her accomplishments. To name a few, she has been honored with the Obama Presidential Lifetime Achievement Award 2016, Obama Presidential Gold Award, Word of Life United Nations Ambassadors Award, and President Donald Trump Lifetime Achievement Award 2019, Biden Presidential Lifetime Achievement Award 2022, The Forbes Business Council Award, Outstanding Georgia Ambassador Award 2020, The Top 25 Women award from Courageous Woman Magazine, Leading Woman of Wealth Award by Women of Wealth Magazine, several proclamations and recognitions from Governors, Senators, and House of Representatives, and several others. This year she will be considered for the Empowered Woman Award and to be featured in TIP (Top Industry Professionals) Magazine. She will be honored at IAOTP’s annual awards gala in Nashville at the Opryland Resort next December for her selection as Top Transformational Business and Life Strategist Advocate of the Year.

In addition to her successful career, Dr. Mohair is fueled by a passion for fulfilling God’s mandate for these turbulent times. Her thrust on character building by merging spirituality with everyday living provokes people to pursue a life of integrity. Wherever she goes, Dr. Mohair exhorts and encourages her listeners to deepen their intimacy with God and arise to their divine appointment, calling, and destiny. She also spends much of her time volunteering with the Red Cross. She is the chancellor of TIUA School of Business, Trinity International University of Ambassadors, a co-founder of the Trinity Girls Network Corporation, and a Board Member of the Whitney E. Houston Legacy Foundation, which empowers the youth to restore self-esteem, rebuild lives, and repair images through grassroots programs and initiatives. Her motto “The Children are our Future”.

The President of the International Association of Top Professionals (IAOTP), Stephanie Cirami, stated: “Choosing Dr. Mohair for this honor was an easy decision for our panel to make. She is inspirational, influential, and a true visionary and thought leader. We cannot wait to meet her and celebrate her accomplishments at next year’s gala.”

Looking back, Dr. Jacqueline attributes her success to her perseverance, commitment, passion, work ethic, and the mentors she has had along the way. When not working, she enjoys traveling and spending time with her husband, four children, and seven grandchildren. In the future, she hopes to inspire and influence those getting into the field.

For more information please visit: http://www.jacquelinemohair.com/

About IAOTP

The International Association of Top Professionals (IAOTP) is an international boutique networking organization that handpicks the world’s finest, most prestigious top professionals from different industries. These top professionals are given an opportunity to collaborate, share their ideas, be keynote speakers, and to help influence others in their fields. This organization is not a membership that anyone can join. You have to be asked by the President or be nominated by a distinguished honorary member after a brief interview.

IAOTP’s experts have given thousands of top prestigious professionals around the world, the recognition and credibility that they deserve and have helped in building their branding empires. IAOTP prides itself to be a one-of-a-kind boutique networking organization that hand picks only the best of the best and creates a networking platform that connects and brings these top professionals to one place.

For More information on IAOTP please visit: www.iaotp.com

Media Contact
Company Name: IAOTP
Contact Person: Media Relations
Email: Send Email
Phone: (212) 634-4427
Country: United States
Website: https://iaotp.com

Steve Mariotti Selected as Man of the Year of 2024 by IAOTP

Steve Mariotti Selected as Man of the Year of 2024 by IAOTP

Steve Mariotti, Best-Selling Author, Founder of the Global Nonprofit Network For Teaching Entrepreneurship (NFTE), and CEO of Atlas Learning was recently selected as Man of the Year for 2024 by the International Association of Top Professionals (IAOTP). His expertise and extraordinary talents have afforded him this distinction.

While inclusion with the International Association of Top Professionals is an honor in itself, only 1 male professional is selected as Man of the Year. The Man of the Year Award signifies IAOTP’s most outstanding male member who has gone above and beyond excellence not only in his field but has demonstrated success professionally, personally and has been a leader in his community. This man has made an impact on people’s lives around the world and for 2024 IAOTP is proud to give this award to Mr. Steve Mariotti.

Mr. Steve Mariotti was just recently announced as Man of the Year at IAOTP’s 2024 at the Annual Awards Gala which was held at the Plaza Hotel in New York City. He is also a prestigious member of the exclusive Hall of Fame club.

www.iaotp.com/award-gala

Mr. Mariotti received this honor because his career has touched practically every business sector. Through his organization NFTE and the millions of copies of his books sold, he has taught millions about entrepreneurship and business ownership. He began as the company’s youngest senior analyst before directing a team in Ford’s International Finance Department that established methods that are still in use today to reduce the company’s borrowing costs and save over $2 million per year. Mr. Mariotti also collaborated with famed civil rights leader and social activist Leon Sullivan to design elements of Ford’s inaugural anti-apartheid strategy in 1979. Mr. Mariotti then departed Ford Motor Company to launch Mason Import/Export Services in New York City. Mr. Mariotti felt driven to educate and help urban youngsters, so he sold his business and became a special education teacher in some of New York City’s most challenging communities, including Bedford-Stuyvesant, the South Bronx, and the Lower East Side.

Mr. Mariotti founded the South Bronx Entrepreneurial Education Project, Inc. in 1987 in a South Bronx classroom dedicated to high school dropouts, which subsequently became the National Foundation for Teaching Entrepreneurship, a charity popularly known as NFTE and pronounced (Nifty). NFTE aims to teach low-income adolescents the fundamentals of entrepreneurship and wealth development so they can find their road to success. Mr. Mariotti’s textbooks and curriculum are used in 22 states and 12 countries, and NFTE has served over 1,000,000 students worldwide with entrepreneurship education. Mr. Mariotti’s curriculum has been used to train over 12,000 teachers around the world.

Mr. Mariotti and Mr. Joseph Robinson co-founded Inmates Teaching Business and Mentorship (ITEM) in 1995 after teaching math and entrepreneurship at Rikers Island, New York City’s main jailing facility and one of the largest jails in America. ITEM is a prison-based program that teaches inmates how to educate their children and fellow offenders on the fundamentals of company ownership. This concept was quickly replicated in other jails and has since become a national model.

Mr. Mariotti is a sought-after speaker, lecturer, and regular contributor to the Huffington Post. He has published numerous articles and has co-authored / authored 43 books and manuals. Steve has served as a motivational coach to empower entrepreneurs worldwide. He has spoken as an entrepreneurship expert at the Aspen Ideas Festival, Harvard, Columbia, Yale, Brown, Berkeley, Georgetown, Baylor, and Babson College. Mr. Mariotti has also traveled to Southeast Asia as a US State Department guest to share his entrepreneurial education with emerging economies. Mr. Mariotti’s recent works and Amazon #1 Best-Selling books include “Profiles in Grit: Why Entrepreneurs Triumph Over Trauma” and “Goodbye Homeboy: How My Students Drove Me Crazy and Inspired a Movement.”

Throughout his illustrious career, Mr. Mariotti has received several awards, accolades and has been recognized globally for his remarkable leadership and commitment to the profession.  As an IAOTP member, Mr. Mariotti was recognized numerous times. In 2022 he was named Top Author of the Year and was inducted into the prestigious IAOTP Hall of Fame. He also appeared on the Planet Hollywood Billboard on the Las Vegas Strip, and graced the cover of TIP (Top Industry Professionals) Magazine.   In 2020, he received the Lifetime Achievement Award, was selected as Top Global Education Social Entrepreneur of the Decade and the Top Global Social Entrepreneur of the Year. In 2019, he was honored at the Bellagio Hotel for being named Top Entrepreneur of the Year by the International Association of Top Professionals and featured on the renowned Reuters Building in Times Square. This year Mr. Mariotti will be interviewed for an exclusive interview on TIP Radio. He has also received the Bernard A. Goldhirsh Social Entrepreneur of the Year Award, the United States Department of Commerce’s National Director’s Entrepreneurship Award, the Ernst & Young Entrepreneur of the Year Award, the ACE/Currie Foundation’s Humanitarian Venture Award, the Salvatori Award, and the Society of Entrepreneurial Educators’ (SEE) first award for Outstanding Educator. Mr. Mariotti has been included in numerous editions of Who’s Who in America, Who’s Who in Finance and Business, and Who’s Who in the World.

Looking back, Mr. Mariotti credits his success to his education, mentors he met along the way, and a desire to serve others. He finds his work very rewarding and hopes others will seek a career as a teacher in low-income regions. In his spare time, Steve enjoys chess, hiking, collecting rare books, and attending seminars at Princeton’s Institute for Advanced Studies. He hopes to continue making a difference in people’s lives in any way he can.

For more information on Mr. Mariotti, please visit: 

https://www.linkedin.com/in/stevemariotti/

To view his Video Biography, please visit: 

https://youtu.be/G71ypwPkW1I

https://www.youtube.com/watch?v=vShjTvPaIzw&t=1s

About IAOTP 

The International Association of Top Professionals (IAOTP) is an international boutique networking organization that handpicks the world’s finest, most prestigious top professionals from different industries. These top professionals are given an opportunity to collaborate, share their ideas, be keynote speakers and to help influence others in their fields. This organization is not a membership that anyone can join. You must be asked by the President or be nominated by a distinguished honorary member after a brief interview.  

IAOTP’s experts have given thousands of top prestigious professionals worldwide the recognition and credibility that they deserve and have helped build their branding empires. IAOTP prides itself on being a one-of-a-kind boutique networking organization that handpicks only the best of the best and creates a networking platform that connects and brings these top professionals together.

For more information on IAOTP, please visit: www.iaotp.com

Media Contact
Company Name: IAOTP
Contact Person: Media Relations
Email: Send Email
Phone: (212) 634-4427
Country: United States
Website: https://iaotp.com

StartupBreed: Revolutionizing Talent Acquisition for Startups and SMEs in Bangkok with Expert Headhunting Services


Pictured, Charlie Withayachamnankul (left), Billy van der Loo (right), Founders of StartupBreed

The entrepreneurial landscape is fiercely competitive, especially for startups and SMEs striving for growth and innovation. Recognizing the critical need for exceptional talent in this sector, Bangkok-based StartupBreed Recruitment emerges as a pioneering headhunting agency. Their unique focus? Identifying and recruiting mid to senior-level professionals possessing a distinct entrepreneurial spirit, essential for leading startups, progressive SMEs, and innovative business units.

Co-founded by industry veterans Charlie Withayachamnankul and Billy van der Loo, who have both successfully built and exited startups, StartupBreed is not just another recruitment firm. It’s an agency born out of real-world experiences and an intimate understanding of the challenges in the startup ecosystem. “We’re addressing major issues in the talent market,” Charlie states. “StartupBreed excels in finding individuals with the right entrepreneurial mindset – a crucial element for the success of high-growth companies.”

For smaller startups and SMEs, the challenge of attracting the right talent is daunting. StartupBreed specializes in this area. “Our expertise lies in collaborating with startups across various industries and developmental stages, from nascent pre-seed ventures to established unicorns, including new-generation SMEs and even public companies,” says Charlie.

Clients seeking talent through StartupBreed range from those looking for mid-level professionals commanding salaries upwards of 40,000 baht, to Chief Marketing Officers earning over 500,000 baht plus equity options.

However, StartupBreed’s services extend far beyond mere headhunting. Operating with the agility and innovation of a startup itself, the company offers comprehensive consulting on talent acquisition strategies. This includes organizational chart development, team structuring, and crafting competitive employee benefits packages, ensuring that their clients are well-equipped to attract and retain top-tier talent.

In the current market, the demand for skilled professionals is outpacing supply. “Employers must go the extra mile to attract and retain top talent,” observes Billy. “With the tech sector particularly volatile, professionals often leverage their skills for better offers, leading to frequent job changes.”

Another trend shaping the industry is the growing preference for remote work among tech professionals, contrasted with companies’ desire for in-office collaboration. “Thailand boasts a wealth of talent, yet there’s a gap in terms of skill sets matching market needs. Improving English proficiency is also crucial for local startups aiming to compete regionally,” adds Billy.

As StartupBreed continues to bridge these gaps, they stand as a beacon of hope and a strategic partner for startups and SMEs in Bangkok and beyond, propelling them towards growth and success in a challenging market.

About StartupBreed Recruitment

StartupBreed Recruitment is a Bangkok-based headhunting agency specializing in sourcing mid to senior-level talent with an entrepreneurial mindset for startups, SMEs, and innovative business units. With a deep understanding of the unique challenges faced by startups, the agency provides tailored recruitment solutions and strategic consulting services to help businesses thrive in a competitive landscape.

Media Contact:

StartupBreed Recruitment (Under Resubae Recruitment Co., Ltd.)

M.Thai Tower All Seasons Place, 23rd floor, Office TT01, 87 Witthayu Rd, Lumphini, Phatumwan, Bangkok 10330

+66 2627 9000

info@startupbreed.com, billy@startupbreed.com 

https://startupbreed.com/ 

Media Contact
Company Name: StartupBreed Recruitment (Under Resubae Recruitment Co., Ltd.)
Contact Person: Media Relations
Email: Send Email
Country: Thailand
Website: https://startupbreed.com/

Acute Kidney Injury Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Alloksys, Guard Therapeutics, Ocelot Bio, Angion Biomedica, Vifor Pharma

“Acute Kidney Injury Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Acute Kidney Injury, historical and forecasted epidemiology.

DelveInsight’s “Acute Kidney Injury Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Acute Kidney Injury, historical and forecasted epidemiology as well as the Acute Kidney Injury market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Acute Kidney Injury market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acute Kidney Injury Market Forecast

 

Some of the key facts of the Acute Kidney Injury Market Report: 

  • The Acute Kidney Injury market size was valued approximately USD 5,208 million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In 2022, the adjusted incident population of Acute Kidney Injury in hospitalized patients across the seven major markets was estimated to be approximately 6,485,000.
  • The United States holds the largest incident population of Acute Kidney Injury among hospitalized patients, surpassing EU4, the UK, and Japan. Specifically, in 2022, the adjusted incident population of Acute Kidney Injury in hospitalized patients in the United States was estimated at approximately 2,215,000. Additionally, in the US during the same year, there were roughly 1,570,000, 398,000, and 243,000 cases of Stage I, Stage II, and Stage III Acute Kidney Injury, respectively
  • In the United States, the age bracket of 60–84 years had the highest number of cases in 2022, followed by those aged 85 and above. Conversely, the fewest cases were observed in the 18–59 age group. Specifically, in 2022, there were approximately 309,000, 995,000, and 906,000 cases reported for the age groups of 18–59 years, 60–84 years, and 85 years and above, respectively.
  • Currently, there are no approved targeted pharmacotherapies specifically designated for the treatment of AKI. The therapeutic landscape for AKI primarily relies on Renal Replacement Therapy (RRT) and off-label drugs, which encompass various classes such as ACE inhibitors, Angiotensin II-Receptor Blockers (ARBs), Diuretics, and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
  • Key Acute Kidney Injury Companies: Alloksys, Guard Therapeutics, Ocelot Bio, Angion Biomedica/Vifor Pharma AM Pharma, Astellas Pharma, Sentien Biotechnologies, RegeneRx Biopharmaceuticals, and others
  • Key Acute Kidney Injury Therapies: bRESCAP, RMC-035 (ROSgard), OCE-205, ANG-3777, Ilofotase alfa, ASP1128, SBI-101, Timbetasin, and others 
  • The Acute Kidney Injury market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acute Kidney Injury pipeline products will significantly revolutionize the Acute Kidney Injury market dynamics.

 

Acute Kidney Injury Overview

Acute renal failure (ARF), sometimes referred to as acute kidney injury (AKI), is a medical illness typified by progressive azotemia that can occur with or without oliguria over the course of several hours or days. Acute kidney injury (AKI) is a medical condition characterized by a sudden decrease in kidney function and a transient, reversible rise in nitrogen waste products as determined by blood ureanitrogen (BUN) and serum creatinine levels over a period of hours to weeks.

 

Get a Free sample for the Acute Kidney Injury Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/acute-kidney-injury-aki-market

 

Acute Kidney Injury Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Acute Kidney Injury Epidemiology Segmentation:

The Acute Kidney Injury market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Acute Kidney Injury
  • Prevalent Cases of Acute Kidney Injury by severity
  • Gender-specific Prevalence of Acute Kidney Injury
  • Diagnosed Cases of Episodic and Chronic Acute Kidney Injury

 

Download the report to understand which factors are driving Acute Kidney Injury epidemiology trends @ Acute Kidney Injury Epidemiology Forecast

 

Acute Kidney Injury Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Kidney Injury market or expected to get launched during the study period. The analysis covers Acute Kidney Injury market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Acute Kidney Injury Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Acute Kidney Injury Therapies and Key Companies

  • bRESCAP: Alloksys
  • RMC-035 (ROSgard): Guard Therapeutics
  • OCE-205: Ocelot Bio
  • ANG-3777: Angion Biomedica/Vifor Pharma
  • Ilofotase alfa: AM Pharma
  • ASP1128: Astellas Pharma       
  • SBI-101: Sentien Biotechnologies         
  • Timbetasin: RegeneRx Biopharmaceuticals      

 

Discover more about therapies set to grab major Acute Kidney Injury market share @ Acute Kidney Injury Treatment Landscape

 

Acute Kidney Injury Market Strengths

  • The pipeline of AKI is quite robust with diverse products strengthening the upcoming market.
  • The treatment related adverse events are very nominal resulting into effective treatment options

 

Acute Kidney Injury Market Opportunities

  • Several biomarkers such as NGAL, Cystatin-C, etc. are being tried and tested to diagnose AKI. Validation of these new biomarkers could provide additional tools to detect the onset and severity of kidney injury

 

Scope of the Acute Kidney Injury Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Acute Kidney Injury Companies: Alloksys, Guard Therapeutics, Ocelot Bio, Angion Biomedica/Vifor Pharma AM Pharma, Astellas Pharma, Sentien Biotechnologies, RegeneRx Biopharmaceuticals, and others
  • Key Acute Kidney Injury Therapies: bRESCAP, RMC-035 (ROSgard), OCE-205, ANG-3777, Ilofotase alfa, ASP1128, SBI-101, Timbetasin, and others
  • Acute Kidney Injury Therapeutic Assessment: Acute Kidney Injury current marketed and Acute Kidney Injury emerging therapies
  • Acute Kidney Injury Market Dynamics: Acute Kidney Injury market drivers and Acute Kidney Injury market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Acute Kidney Injury Unmet Needs, KOL’s views, Analyst’s views, Acute Kidney Injury Market Access and Reimbursement 

 

To know more about Acute Kidney Injury companies working in the treatment market, visit @ Acute Kidney Injury Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Acute Kidney Injury Market Report Introduction

2. Executive Summary for Acute Kidney Injury

3. SWOT analysis of Acute Kidney Injury

4. Acute Kidney Injury Patient Share (%) Overview at a Glance

5. Acute Kidney Injury Market Overview at a Glance

6. Acute Kidney Injury Disease Background and Overview

7. Acute Kidney Injury Epidemiology and Patient Population

8. Country-Specific Patient Population of Acute Kidney Injury 

9. Acute Kidney Injury Current Treatment and Medical Practices

10. Acute Kidney Injury Unmet Needs

11. Acute Kidney Injury Emerging Therapies

12. Acute Kidney Injury Market Outlook

13. Country-Wise Acute Kidney Injury Market Analysis (2019–2032)

14. Acute Kidney Injury Market Access and Reimbursement of Therapies

15. Acute Kidney Injury Market Drivers

16. Acute Kidney Injury Market Barriers

17.  Acute Kidney Injury Appendix

18. Acute Kidney Injury Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Kidney Injury Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Alloksys, Guard Therapeutics, Ocelot Bio, Angion Biomedica, Vifor Pharma

Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Sunovion Pharmaceuticals, Vanda Pharma

“Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Psychosis in Parkinson’s Disease and Alzheimer’s Disease, historical and forecasted epidemiology.

DelveInsight’s “Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Psychosis in Parkinson’s Disease and Alzheimer’s Disease, historical and forecasted epidemiology as well as the Psychosis in Parkinson’s Disease and Alzheimer’s Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Psychosis in Parkinson’s Disease and Alzheimer’s Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Forecast

 

Some of the key facts of the Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Report: 

  • The Psychosis in Parkinson’s Disease and Alzheimer’s Disease market size was valued approximately USD 1,229 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • Acadia’s NUPLAZID (pimavanserin) stands as the sole approved product for PDP (Parkinson’s Disease Psychosis) in the US. While it is still under investigation for ADP (Alzheimer’s Disease Psychosis), it carries a boxed warning concerning heightened mortality risks observed in elderly patients with psychosis related to dementia.
  • Several medications are in various stages of development to address psychosis in Parkinson’s Disease and Alzheimer’s Disease, yet only a limited number are in advanced stages. Examples include Karuna Therapeutics’ KarXT (xanomeline-trospium), Sunovion Pharmaceuticals’ Ulotaront (SEP-363856), and Vanda Pharmaceuticals’ FANAPT (iloperidone). These are expected to be introduced to the market within the forecast period spanning from 2023 to 2032.
  • In 2022, the combined diagnosed prevalent cases of Psychosis in PD (Parkinson’s Disease) and AD (Alzheimer’s Disease) across the 7MM reached around 6,737,337 cases. Projections indicate an anticipated increase by 2032 at a Compound Annual Growth Rate (CAGR) of 2.4% throughout the study period from 2019 to 2032.
  • In 2022, the United States represented approximately 34% of the diagnosed prevalent cases of Psychosis in PD (Parkinson’s Disease) and AD (Alzheimer’s Disease) within the 7MM. This proportion is anticipated to rise further by the year 2032.
  • In the United States, there were an estimated 675,948 cases in males and 503,305 cases in females affected by PD (Parkinson’s Disease) in 2022. These figures are projected to rise by the year 2032
  • In the year 2022, the number of AD (Alzheimer’s Disease) cases among males in EU4 and the UK was approximately 1,454,541, while among females, it reached nearly 3,487,835 cases. These figures are anticipated to increase by the year 2032.
  • In 2022, Germany contributed to roughly 18% of the total diagnosed prevalent cases of PD (Parkinson’s Disease) within the 7MM. These cases are projected to rise at a Compound Annual Growth Rate (CAGR) of 1.7% during the study period from 2019 to 2032.
  • Key Psychosis in Parkinson’s Disease and Alzheimer’s Disease Companies: Karuna Therapeutics, Sunovion Pharmaceuticals, Vanda Pharmaceuticals, Intra-Cellular Therapeutics, Merck Sharp & Dohme, and others
  • Key Psychosis in Parkinson’s Disease and Alzheimer’s Disease Therapies: KarXT, Ulotaront, FANAPT, ITI-1284, MK-8189, and others
  • The Parkinson’s Disease epidemiology based on gender analyzed that in the US, males diagnosed with PD are higher in number than females
  • The Psychosis in Parkinson’s Disease and Alzheimer’s Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Psychosis in Parkinson’s Disease and Alzheimer’s Disease pipeline products will significantly revolutionize the Psychosis in Parkinson’s Disease and Alzheimer’s Disease market dynamics.

 

Psychosis in Parkinson’s Disease and Alzheimer’s Disease Overview

The National Institute of Mental Health (NIMH) defines psychosis as a group of symptoms affecting the mind in which there has been a partial loss of reality awareness. People have disruptions in their thoughts and perceptions during a psychotic episode, making it difficult for them to distinguish between reality and illusion.

In Parkinson’s disease (PD) and Alzheimer’s disease (AD), psychosis develops as a result of both endogenous (associated with the disease process) and exogenous (drugs, for example).

 

Get a Free sample for the Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/psychosis-in-parkinsons-and-alzheimers-disease-market

 

Psychosis in Parkinson’s Disease and Alzheimer’s Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Psychosis in Parkinson’s Disease and Alzheimer’s Disease Epidemiology Segmentation:

The Psychosis in Parkinson’s Disease and Alzheimer’s Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Psychosis in Parkinson’s Disease and Alzheimer’s Disease
  • Prevalent Cases of Psychosis in Parkinson’s Disease and Alzheimer’s Disease by severity
  • Gender-specific Prevalence of Psychosis in Parkinson’s Disease and Alzheimer’s Disease
  • Diagnosed Cases of Episodic and Chronic Psychosis in Parkinson’s Disease and Alzheimer’s Disease

 

Download the report to understand which factors are driving Psychosis in Parkinson’s Disease and Alzheimer’s Disease epidemiology trends @ Psychosis in Parkinson’s Disease and Alzheimer’s Disease Epidemiology Forecast

 

Psychosis in Parkinson’s Disease and Alzheimer’s Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Psychosis in Parkinson’s Disease and Alzheimer’s Disease market or expected to get launched during the study period. The analysis covers Psychosis in Parkinson’s Disease and Alzheimer’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Psychosis in Parkinson’s Disease and Alzheimer’s Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Psychosis in Parkinson’s Disease and Alzheimer’s Disease Therapies and Key Companies

  • KarXT: Karuna Therapeutics
  • Ulotaront: Sunovion Pharmaceuticals
  • FANAPT: Vanda PharmaceuticalsF
  • ITI-1284: Intra-Cellular Therapeutics
  • MK-8189: Merck Sharp & Dohme

 

Discover more about therapies set to grab major Psychosis in Parkinson’s Disease and Alzheimer’s Disease market share @ Psychosis in Parkinson’s Disease and Alzheimer’s Disease Treatment Landscape

 

Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Strengths

  • Increased awareness and a more in-depth understanding of the disease pathophysiology has improved diagnosis and treatment.
  • The recent US FDA approval of NUPLAZID, the first approved therapy for treating hallucinations and delusions associated with PD Psychosis, indicates a positive change in treatment paradigm.

 

Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Opportunities

  • There are opportunities for pharma players to develop therapies with improved safety and tolerability profiles, effectively reducing symptoms and preventing the recurrence of Psychosis in PD and AD.
  • Advancement in biomarkers for cognitive decline allows precise diagnosis and individualized treatments

 

Scope of the Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Psychosis in Parkinson’s Disease and Alzheimer’s Disease Companies: Karuna Therapeutics, Sunovion Pharmaceuticals, Vanda Pharmaceuticals, Intra-Cellular Therapeutics, Merck Sharp & Dohme, and others
  • Key Psychosis in Parkinson’s Disease and Alzheimer’s Disease Therapies: KarXT, Ulotaront, FANAPT, ITI-1284, MK-8189, and others
  • Psychosis in Parkinson’s Disease and Alzheimer’s Disease Therapeutic Assessment: Psychosis in Parkinson’s Disease and Alzheimer’s Disease current marketed and Psychosis in Parkinson’s Disease and Alzheimer’s Disease emerging therapies
  • Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Dynamics: Psychosis in Parkinson’s Disease and Alzheimer’s Disease market drivers and Psychosis in Parkinson’s Disease and Alzheimer’s Disease market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Psychosis in Parkinson’s Disease and Alzheimer’s Disease Unmet Needs, KOL’s views, Analyst’s views, Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Access and Reimbursement 

 

To know more about Psychosis in Parkinson’s Disease and Alzheimer’s Disease companies working in the treatment market, visit @ Psychosis in Parkinson’s Disease and Alzheimer’s Disease Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Report Introduction

2. Executive Summary for Psychosis in Parkinson’s Disease and Alzheimer’s Disease

3. SWOT analysis of Psychosis in Parkinson’s Disease and Alzheimer’s Disease

4. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Patient Share (%) Overview at a Glance

5. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Overview at a Glance

6. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Disease Background and Overview

7. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Psychosis in Parkinson’s Disease and Alzheimer’s Disease 

9. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Current Treatment and Medical Practices

10. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Unmet Needs

11. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Emerging Therapies

12. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Outlook

13. Country-Wise Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Analysis (2019–2032)

14. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Access and Reimbursement of Therapies

15. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Drivers

16. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Barriers

17.  Psychosis in Parkinson’s Disease and Alzheimer’s Disease Appendix

18. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Navdha Goel
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Sunovion Pharmaceuticals, Vanda Pharma

EcoCare integrates digital technologies to help customers accomplish decarbonization goals, optimize maintenance: Schneider Electric

Schneider Electric, a leader in digital transformation of energy management and automation, recently announced EcoCare, a new level of access to electrical system expertise.

EcoCare membership is for customers who demand proactive management of their systems to drive higher performance, resilience and safety, and a smaller carbon footprint. EcoCare gives its members fast and exclusive access to the best experts. Its members receive an optimal service level, deep insights on asset conditions, and world class expertise to unlock safety, efficiency and sustainability improvements.

Ramesh Kumar Jha, VP, Services Business, Schneider Electric India, tells us more. Excerpts from an interview:

DQ: Please highlight the key technological trends anticipated in 2024, especially those relevant to industrial enterprise operations and maintenance.

Ramesh Kumar Jha: We see two key trends for 2024, first is the accelerated transformation from traditional calendar-based maintenance towards condition-based maintenance by continuous monitoring of equipment parameters through digital and IoT sensors, and applying data analytics to predict when the maintenance is needed or not needed, also predicting faults and breakdowns before they happen.

Second, industries are increasingly embracing the transition to the fourth industrial revolution, emphasizing the imperative of bridging IT-OT integration. This shift necessitates leveraging advanced analytics to enhance efficiency, reliability, and agility in day-to-day operations.

DQ: Can you elaborate on emerging technologies such as advanced data analytics, predictive maintenance solutions, and the integration of IoT for enhanced efficiency?

Ramesh Kumar Jha: Digital capabilities like advanced data analytics and predictive maintenance based on IoT technologies empower customers to deliver insights derived from connected technologies, thereby users with a in depth understanding of their systems. Making the right choices at right moments emerges as a pivotal catalyst towards enhanced economic and operational advantages

Unexpected breakdowns and downtimes are major hurdles affecting the efficiency and productivity of an asset. This can take a heavy toll on operational costs. Therefore, strategic investment in efficient maintenance and high-quality systems becomes pivotal for deriving strong business value, both from a capital expenditure (CapEx) and operating expenditure (OpEx) perspective.

This principle underscores the foundation of Schneider Electric’s EcoCare Services Membership in India. Through our EcoCare services, we are dedicated to empowering Indian businesses to innovate without the encumbrance of maintenance concerns.

DQ: How does EcoCare align with the identified technological trends for 2024?

Ramesh Kumar Jha: EcoCare’s cutting-edge digital capabilities empower us to deliver insights derived from our connected technologies with the help of these advanced digital capabilities, EcoCare stands out as a proactive solution at a time when operations must be robust, efficient, continuous, and sustainable.

The solution immediately responds to the growing need for real-time insights and predictive analytics in facility management with its emphasis on condition-based maintenance, faster reaction times, and 24/7 remote monitoring. EcoCare gives companies special access to experts, and integrates the latest digital technologies to help them accomplish their decarbonization goals, optimize maintenance, and enhance system efficiency.

Furthermore, in an age of customized and scalable solutions, EcoCare’s tiers of products, which span from Essential to Advanced and +Advanced, demonstrate a thorough grasp of a variety of client needs. As a result of Schneider Electric’s commitment to efficiency, sustainability, and digital transformation, EcoCare is well-positioned as a vital partner for companies looking to navigate the rapidly changing technological landscape without any breaks.

DQ: What are the specific features within EcoCare that leverage advanced technologies to address challenges in industrial operations and maintenance?

Ramesh Kumar Jha: Schneider Electric’s EcoCare service membership leverages advanced digital technologies to minimize downtime by up to ~75% and reduce planned downtime by 40%. With EcoCare’s round-the-clock remote monitoring capabilities, you can see the whole picture of critical infrastructure and take proactive steps to identify and address possible problems before they become serious enough to cause downtime.

This is complemented by unique EcoCare offer of guaranteed SLA of being on site in case of any emergency. Overall, by minimizing unscheduled downtime, this ongoing surveillance guarantees business continuity and continuing operations right from Day 1 of the equipment.

EcoCare makes traditional maintenance procedures proactive by leveraging data-driven insights and predictive analytics to shift them from reactive to proactive. In order to anticipate probable breakdowns, it evaluates the health data of the equipment. This enables dynamic maintenance scheduling, which targets problems precisely when they arise.

With this approach, assets have a longer lifespan, downtime is decreased, and resource allocation is made more effective.

Further, EcoCare provides access to a unique personalized digital experience through the mySchneider portal with visibility of assets under management and membership benefits like priority support, complementary trainings, and discounts on spares.

In summary, our EcoCare membership goes beyond simple equipment upkeep and monitoring, enabling businesses to maximize the efficiency of their systems. Expert suggestions based on real-time data analysis and insights from Schneider Electric’s vast knowledge base help companies increase operational effectiveness, save energy, and meet their sustainability goals. Businesses can deal with changing industry demands in the face of more intricate and interconnected activities by utilizing EcoCare’s innovative solutions.

Media Contact
Company Name: ABC Private Limited
Contact Person: Media Relations
Email: Send Email
Country: India
Website: https://www.se.com/in/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: EcoCare integrates digital technologies to help customers accomplish decarbonization goals, optimize maintenance: Schneider Electric

BestKru Adds “Click-to-Listen” to Improve Japanese Pronunciation

“BestKru Logo”
BestKru, a leading online language learning platform, unveils an innovative “Click-to-Listen” feature in its free Japanese course. Integrating native accent pronunciation, the feature enhances auditory skills, providing an immersive supplement to private tutoring, group classes, and online/in-person learning. BestKru continues to redefine language education, fostering a dynamic and comprehensive Japanese learning experience.

BestKru, a leading language learning and tutoring platform in Thailand, is thrilled to announce the launch of a “Click-to-Listen” feature for its free online Japanese course. This exciting addition aims to enhance the overall learning experience for users by providing an immersive and interactive way to master Japanese pronunciation with a native accent.

The “Click-to-Listen” feature is seamlessly integrated into selected lessons, allowing learners to hear the correct pronunciation of individual Japanese words or entire sentences at the click of a button. This functionality enables users to develop their auditory skills, refine their pronunciation, and build confidence in their Japanese language journey.

Key features of the “Click-to-Listen” feature include:

  • Native Accent Pronunciation: Users can now listen to words and sentences pronounced with a native Japanese accent, providing an authentic language experience.
  • Interactive Learning: The feature promotes interactive learning by allowing users to practice pronunciation in real-time, reinforcing their understanding of Japanese language nuances.
  • User-Friendly Interface: The “Click-to-Listen” button is strategically placed within lessons for easy access, ensuring a smooth and intuitive learning process.
  • Selected Lessons Integration: The feature is currently available in selected lessons, with plans to expand its implementation across the entire free online Japanese course in the near future.

Commenting on the new feature, Kamonwan Achjanis, CMO at BestKru, expressed enthusiasm for the positive impact it will have on learners. “We are committed to providing an exceptional language learning experience, and the ‘Click-to-Listen’ feature represents a significant leap forward in achieving that goal. By integrating native Japanese accent pronunciation into our lessons, we empower users to not only read and write but also speak Japanese with confidence.”

The introduction of the “Click-to-Listen” feature is poised to become an invaluable addition to BestKru’s comprehensive suite of Japanese language learning options, complementing existing methods such as private tutoring, group classes, both online and in-person. While private tutors offer personalized guidance and group classes provide a collaborative learning environment, the “Click-to-Listen” feature uniquely contributes to the auditory dimension of language acquisition. By allowing users to hear authentic native pronunciations with a simple click, this feature offers a dynamic supplement to traditional learning approaches, fostering a well-rounded and immersive language learning experience.

To learn more about English language education services on BestKru, visit https://bestkru.com/ภาษาญี่ปุ่น/

About BestKru

BestKru is a Thai website that helps you find tutors, private teachers, and learning centers for over 50 various subjects, including languages, science, art, music, sports and computers. Founded in 2014, BestKru aims to make quality education accessible and affordable for everyone in Thailand. Students can choose to learn online, at home or school, according to their preferences and schedule. Learners can see the list of popular tutors and schools, their profiles, ratings, and prices on the website, and contact teachers directly to arrange the learning sessions.

Media Contact
Company Name: BestKru
Contact Person: Kamonwan Achjanis
Email: Send Email
Country: Thailand
Website: https://bestkru.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: BestKru Adds \”Click-to-Listen\” to Improve Japanese Pronunciation

Ace Neuroscience Unveils Antipsychotic Drug Development Services to Boost Mental Illness Research

Ace Neuroscience proudly releases its new antipsychotic drug development services to facilitate mental illness research.

Ace Neuroscience, a reliable partner in the development of antipsychotic drugs, proudly releases its new antipsychotic drug development services. With a commitment to advancing mental illness research, the company aims to provide cutting-edge solutions to address the unmet needs of patients and researchers in the field.

In recent years, mental illnesses have gained global attention due to their increasing prevalence and impact on individuals and societies. Effective antipsychotic drugs play a vital role in managing conditions like depression, addiction, schizophrenia, anxiety, and bipolar disorder. Recognizing the urgency and importance of this field, Ace Neuroscience is leveraging its expertise and resources to contribute to the development of innovative solutions.

The antipsychotic drug development services offered by Ace Neuroscience encompass a comprehensive suite of research and development capabilities. This includes diagnosis of mental illness and behavioral analysis, animal model construction, preclinical imaging, biomarker testing, as well as a series of supporting products such as neurotransmitter-associated enzymes and small molecule drugs. By integrating state-of-the-art technologies and scientific expertise, Ace Neuroscience aims to accelerate the process of developing novel antipsychotic drugs to improve patient outcomes and quality of life.

“We know the urgent need for novel antipsychotic drugs that can effectively address the complex nature of psychiatric disorders. In the past few years, we actively collaborate with pharmaceutical industry partners, academic institutions, and governmental organizations to foster a dynamic environment for research and development,” said a senior scientist at Ace Neuroscience. “Our team is committed to conducting rigorous preclinical research to ensure the safety and efficacy of potential drug candidates. We adhere to the highest ethical standards and regulatory guidelines, guaranteeing that our findings are reliable and reproducible.”

Ace Neuroscience’s cutting-edge facilities and dedicated team of experts are equipped to meet the demands of pharmaceutical industry partners, academic institutions, and governmental organizations seeking to develop antipsychotic drugs. With an unwavering commitment to innovation and a deep understanding of the complex mechanisms underlying mental illnesses, Ace Neuroscience is well-positioned to drive breakthroughs in this field.

About Ace Neuroscience

Ace Neuroscience is committed to supporting researchers in making groundbreaking scientific discoveries and developing new applications to accelerate antipsychotic drug discovery and scientific diagnosis and treatment. By leveraging its expertise and advanced platforms, this company helps clients explore the mysteries of mental illness and shorten the time to antipsychotic drug discovery and research.

Media Contact
Company Name: Ace Neuroscience
Contact Person: Daisy Mostert
Email: Send Email
Country: United States
Website: https://www.advaneuro.com/antipsychotics/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ace Neuroscience Unveils Antipsychotic Drug Development Services to Boost Mental Illness Research

Knee Osteoarthritis Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Novartis, Biosplice Therapeutic, Sorrento Therapeutic, Eli Lilly

“Knee Osteoarthritis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Knee Osteoarthritis, historical and forecasted epidemiology.

DelveInsight’s “Knee Osteoarthritis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Knee Osteoarthritis, historical and forecasted epidemiology as well as the Knee Osteoarthritis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Knee Osteoarthritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Knee Osteoarthritis Market Forecast

 

Some of the key facts of the Knee Osteoarthritis Market Report: 

  • The Knee Osteoarthritis market size was valued approximately USD 13 billion in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • Anticipated launch of potential Knee Osteoarthritis therapies by notable companies, including Techfields (X0002), Taiwan Liposome Company (TLC599), Centrexion Therapeutics (CNTX-4975), Biosplice Therapeutics (Lorecivivint), Ampio Pharmaceuticals (Ampion), Paradigm Biopharmaceuticals (Zilosul), Grünenthal (RTX-GRT7039/Resiniferatoxin), Naturecell (JointStem), and other contenders, might contribute to the market’s expansion of Knee Osteoarthritis in the upcoming years, supported by an expected rise in the prevalent population suffering from knee osteoarthritis.
  • In 2021, the total prevalent population diagnosed with symptomatic Knee Osteoarthritis across the seven major markets reached 47,874,567. The United States reported the highest prevalence with 17,660,391 cases, while the combined cases in EU4 and the UK accounted for 19,946,245 cases.
  • According to the assessment, a greater proportion of mild cases of knee Osteoarthritis was identified across the 7 Major Markets (7MM) in 2021, followed by moderate knee Osteoarthritis. In the United States specifically, the highest number of cases in 2021 was reported for mild knee osteoarthritis, with 7,373,858 cases, followed by moderate Knee Osteoarthritis, totaling 6,562,734 cases
  • In the European Union (EU4) and the United Kingdom (UK) in 2021, the most significant percentage of cases was observed in the age group of 70 years and above, followed by the age categories of 60–69 years and 50–59 years. Specifically, there were 638,280, 1,735,323, 4,328,335, 4,807,045, and 8,437,262 cases documented in the age groups of 18–39 years, 40–49 years, 50–59 years, 60–69 years, and 70 years and above, respectively.
  • Key Knee Osteoarthritis Companies: Bioventus LLC, Akan Biosciences, LLC, Genascence Corporation, Immunis, Inc., Novartis, Biosplice Therapeutics, Sorrento Therapeutics, Inc., Novartis, Celltex Therapeutics Corporation, MiMedx Group, Inc., Rho, Inc., Techfields Pharma Co. Ltd, Eli Lilly and Company, Nature Cell Co. Ltd., Novo Nordisk A/S, Flexion Therapeutics, Inc., Grünenthal GmbH, Tissue Tech Inc., Kolon TissueGene, Inc., Saol Therapeutics Inc, Centrexion Therapeutics, Taiwan Liposome Company, MiMedx, Ampio Pharmaceuticals, ReNu, Medipost, and others
  • Key Knee Osteoarthritis Therapies: TP-001, StroMel, GNSC-001, IMM01-STEM, RHH646, Lorecivivint, Resiniferatoxin, DFV890, Celltex- AdMSCs, Micronized DHACM, X0002, Retatrutide, JointStem, Semaglutide, FX201, RTX-GRT7039, TTAX03, TG-C, SL-1002, CNTX-4975, TLC599, Amniofix, Ampion, Organogenesis, Cartistem, and others
  • The Knee Osteoarthritis epidemiology based on gender analyzed that females are most commonly affected than males in case of Knee Osteoarthritis
  • The Knee Osteoarthritis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Knee Osteoarthritis pipeline products will significantly revolutionize the Knee Osteoarthritis market dynamics.

 

Knee Osteoarthritis Overview

Degenerative joint disease, commonly referred to as osteoarthritis of the knee, is usually caused by articular cartilage gradually losing its structure due to wear and tear. It can be separated into two categories, main and secondary, and is most prevalent in the elderly.

 

Get a Free sample for the Knee Osteoarthritis Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/knee-osteoarthritis-market

 

Knee Osteoarthritis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Knee Osteoarthritis Epidemiology Segmentation:

The Knee Osteoarthritis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Knee Osteoarthritis
  • Prevalent Cases of Knee Osteoarthritis by severity
  • Gender-specific Prevalence of Knee Osteoarthritis
  • Diagnosed Cases of Episodic and Chronic Knee Osteoarthritis

 

Download the report to understand which factors are driving Knee Osteoarthritis epidemiology trends @ Knee Osteoarthritis Epidemiology Forecast

 

Knee Osteoarthritis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Knee Osteoarthritis market or expected to get launched during the study period. The analysis covers Knee Osteoarthritis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Knee Osteoarthritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Knee Osteoarthritis Therapies and Key Companies

  • Retatrutide: Eli Lilly and Company
  • JointStem: Nature Cell Co. Ltd.
  • Semaglutide: Novo Nordisk A/S
  • FX201: Flexion Therapeutics, Inc.
  • RTX-GRT7039: Grünenthal GmbH
  • TTAX03: Tissue Tech Inc.
  • TG-C: Kolon TissueGene, Inc.
  • SL-1002: Saol Therapeutics Inc
  • PTP-001: Bioventus LLC
  • StroMel: Akan Biosciences, LLC
  • GNSC-001: Genascence Corporation
  • IMM01-STEM: Immunis, Inc.
  • RHH646: Novartis
  • Lorecivivint: Biosplice Therapeutics
  • Resiniferatoxin: Sorrento Therapeutics, Inc.
  • DFV890: Novartis
  • Celltex- AdMSCs: Celltex Therapeutics Corporation
  • Micronized DHACM: MiMedx Group, Inc./Rho, Inc.
  • X0002: Techfields Pharma Co. Ltd
  • CNTX-4975: Centrexion Therapeutics
  • TLC599: Taiwan Liposome Company
  • Amniofix: MiMedx
  • Ampion: Ampio Pharmaceuticals
  • Organogenesis: ReNu
  • Cartistem: Medipost

 

Discover more about therapies set to grab major Knee Osteoarthritis market share @ Knee Osteoarthritis Treatment Landscape

 

Knee Osteoarthritis Market Strengths

  • Now companies are investing heavily in developing disease modifying therapies for the treatment of knee osteoarthritis, which will fulfill a major unmet need.
  • Many key players are developing cell therapies for knee osteoarthritis, which are in various stages of development. These therapies, if approved, may provide better treatment options as it can slow disease progression and may possibly cure the disease.

 

Knee Osteoarthritis Market Opportunities

For the treatment of Knee OA, usage of opioids can be seen. The majority of patients/ physicians are eagerly waiting for nonopioids options and key players can target this lucrative segment of the market, while others are already developing therapies for the same.

 

Scope of the Knee Osteoarthritis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Knee Osteoarthritis Companies: Bioventus LLC, Akan Biosciences, LLC, Genascence Corporation, Immunis, Inc., Novartis, Biosplice Therapeutics, Sorrento Therapeutics, Inc., Novartis, Celltex Therapeutics Corporation, MiMedx Group, Inc., Rho, Inc., Techfields Pharma Co. Ltd, Eli Lilly and Company, Nature Cell Co. Ltd., Novo Nordisk A/S, Flexion Therapeutics, Inc., Grünenthal GmbH, Tissue Tech Inc., Kolon TissueGene, Inc., Saol Therapeutics Inc, Centrexion Therapeutics, Taiwan Liposome Company, MiMedx, Ampio Pharmaceuticals, ReNu, Medipost, and others
  • Key Knee Osteoarthritis Therapies: TP-001, StroMel, GNSC-001, IMM01-STEM, RHH646, Lorecivivint, Resiniferatoxin, DFV890, Celltex- AdMSCs, Micronized DHACM, X0002, Retatrutide, JointStem, Semaglutide, FX201, RTX-GRT7039, TTAX03, TG-C, SL-1002, CNTX-4975, TLC599, Amniofix, Ampion, Organogenesis, Cartistem, and others
  • Knee Osteoarthritis Therapeutic Assessment: Knee Osteoarthritis current marketed and Knee Osteoarthritis emerging therapies
  • Knee Osteoarthritis Market Dynamics: Knee Osteoarthritis market drivers and Knee Osteoarthritis market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Knee Osteoarthritis Unmet Needs, KOL’s views, Analyst’s views, Knee Osteoarthritis Market Access and Reimbursement 

 

To know more about Knee Osteoarthritis companies working in the treatment market, visit @ Knee Osteoarthritis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Knee Osteoarthritis Market Report Introduction

2. Executive Summary for Knee Osteoarthritis

3. SWOT analysis of Knee Osteoarthritis

4. Knee Osteoarthritis Patient Share (%) Overview at a Glance

5. Knee Osteoarthritis Market Overview at a Glance

6. Knee Osteoarthritis Disease Background and Overview

7. Knee Osteoarthritis Epidemiology and Patient Population

8. Country-Specific Patient Population of Knee Osteoarthritis 

9. Knee Osteoarthritis Current Treatment and Medical Practices

10. Knee Osteoarthritis Unmet Needs

11. Knee Osteoarthritis Emerging Therapies

12. Knee Osteoarthritis Market Outlook

13. Country-Wise Knee Osteoarthritis Market Analysis (2019–2032)

14. Knee Osteoarthritis Market Access and Reimbursement of Therapies

15. Knee Osteoarthritis Market Drivers

16. Knee Osteoarthritis Market Barriers

17.  Knee Osteoarthritis Appendix

18. Knee Osteoarthritis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Knee Osteoarthritis Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Novartis, Biosplice Therapeutic, Sorrento Therapeutic, Eli Lilly